“The Oxford vaccine is… striking, since the point was to pay researchers, but not to rely on patent monopolies to generate large profits.” – Economist Dean Baker by Alan Macleod Part 3 - More advantages Apart from their willingness to share it with the world freely, the Oxford-AstraZeneca vaccine has other benefits over its competitors. Firstly, they aim to make and sell it for $3-4 per shot, rather than the $20 Pfizer charges, or the $25 for Moderna’s offering. Oxford and AstraZeneca have committed to selling the vaccine to developing countries at cost price. And unlike the costlier Pfizer vaccine, it does not have to be stored at -94 degrees Fahrenheit but can be kept in an ordinary refrigerator, making its storage and distribution straightforward everywhere. Further trials of the vaccine involving 60,000 people in the United States, Kenya, Japan, and India are ongoing. The vaccine is based on a weakened version of a common cold virus and that has been genetically engineered